Zevra Therapeutics, Inc. (ZVRA) Financial Ratios
14 years of historical data (2012–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: 18.60
30Y Low18.6·High18.6
P/FCF
N/A
—
5yr avg: 25.08
30Y Low25.1·High25.1
P/B Ratio
↑
4.07
-3% vs avg
5yr avg: 4.19
30Y Low2.0·High9.7
ROE
↑
85.7%
↓+275% vs avg
5yr avg: -48.8%
30Y Low-208%·High86%
Debt/EBITDA
N/A
—
5yr avg: 0.20
30Y Low0.2·High0.2
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ZVRA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Zevra Therapeutics, Inc. trades at 8.1x earnings, 23% above its 5-year average of 6.6x, sitting at the 100th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.3x, the stock trades at a discount of 64%.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $650M | $513M | $386M | $232M | $158M | $259M | $45M | $11M | $32M | $59M | $43M |
| Enterprise Value | $651M | $514M | $412M | $233M | $112M | $149M | $111M | $88M | $96M | $142M | $118M |
| P/E Ratio → | 8.15 | 6.64 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 6.11 | 4.82 | 16.34 | 8.46 | 15.58 | 9.05 | 3.36 | 0.88 | — | — | — |
| P/B Ratio | 4.07 | 3.32 | 9.72 | 3.75 | 2.11 | 2.04 | — | — | — | — | — |
| P/FCF | — | — | — | — | — | 25.08 | — | — | — | — | — |
| P/OCF | — | — | — | — | — | 24.84 | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ZVRA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 4.83 | 17.46 | 8.48 | 10.98 | 5.18 | 8.35 | 6.82 | — | — | — |
| EV / EBITDA | — | — | — | — | — | 18.60 | — | — | — | — | — |
| EV / EBIT | — | 5.43 | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | 14.37 | — | — | — | — | — |
ZVRA Profitability
Margins and return-on-capital ratios measuring operating efficiency
Zevra Therapeutics, Inc. earns an operating margin of -4.0%. Operating margins have expanded from -180.6% to -4.0% over the past 3 years, signaling improving operational efficiency. Return on equity of 85.7% is exceptionally high.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 84.5% | 84.5% | 68.6% | 89.3% | 97.8% | 92.8% | 90.2% | 77.1% | — | — | — |
| Operating Margin | -4.0% | -4.0% | -368.5% | -180.6% | -418.9% | 27.0% | -42.2% | -158.4% | — | — | — |
| Net Profit Margin | 78.2% | 78.2% | -446.9% | -167.7% | -263.5% | -29.9% | -96.0% | -191.0% | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 85.7% | 85.7% | -207.8% | -67.2% | -26.5% | -28.2% | — | — | — | — | — |
| ROA | 36.0% | 36.0% | -60.2% | -32.0% | -21.6% | -11.9% | -117.5% | -131.7% | -142.6% | -63.2% | -23.5% |
| ROIC | -2.9% | -2.9% | -101.4% | -81.8% | -142.5% | 71.1% | -473.5% | -822.3% | -378.3% | -61.3% | -151.2% |
| ROCE | -2.2% | -2.2% | -71.7% | -49.1% | -36.7% | 11.7% | -128.2% | -205.2% | -200.8% | -56.0% | -59.7% |
ZVRA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $800000 ($63M total debt minus $62M cash). Interest coverage of 11.9x signals virtually no risk of debt distress — earnings comfortably cover interest obligations.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.41 | 0.41 | 1.52 | 0.71 | 0.25 | 0.01 | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | 0.20 | — | — | — | — | — |
| Net Debt / Equity | — | 0.01 | 0.67 | 0.01 | -0.62 | -0.87 | — | — | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | -13.87 | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | -10.71 | — | — | — | — | — |
| Interest Coverage | 11.87 | 11.87 | -11.26 | -29.68 | -79.01 | -21.66 | -0.80 | -2.77 | -7.66 | -4.55 | -4.84 |
ZVRA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Zevra Therapeutics, Inc.'s current ratio of 5.68x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 1.18x to 5.68x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.68 | 5.68 | 2.53 | 1.18 | 7.72 | 27.20 | 1.11 | 1.28 | 1.98 | 3.99 | 11.19 |
| Quick Ratio | 5.63 | 5.63 | 2.47 | 0.85 | 7.72 | 27.20 | 1.11 | 1.28 | 1.98 | 3.99 | 11.03 |
| Cash Ratio | 4.86 | 4.86 | 2.04 | 0.92 | 6.89 | 26.56 | 0.56 | 0.59 | 1.81 | 3.67 | 10.20 |
| Asset Turnover | — | 0.37 | 0.13 | 0.16 | 0.09 | 0.22 | 1.19 | 1.22 | — | — | — |
| Inventory Turnover | 9.47 | 9.47 | 3.76 | 0.12 | — | — | — | — | — | — | 0.16 |
| Days Sales Outstanding | — | 79.73 | 162.45 | 230.97 | 298.11 | 19.47 | 70.84 | 53.02 | — | — | — |
ZVRA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Zevra Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 12.3% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 12.3% | 15.1% | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | 4.0% | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 1.5% | 3.0% | 1.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 1.5% | 3.0% | 1.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $57M | $46M | $35M | $34M | $30M | $4M | $2M | $1M | $915806 | $912315 |
Peer Comparison
Compare ZVRA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ZVRAYou | $650M | 8.1 | — | — | 84.5% | -4.0% | 85.7% | -2.9% | — |
 RARE | $3B | -4.5 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 ACAD | $4B | 9.9 | 26.9 | 36.7 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 PTCT | $5B | 8.3 | 5.4 | 7.6 | 95.9% | 49.5% | — | — | 0.5 |
 KRYS | $9B | 43.4 | 49.2 | 46.3 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 ACHC | $2B | -2.0 | 8.3 | — | 17.6% | 11.7% | -41.4% | 5.9% | 4.6 |
 ACRS | $586M | -9.2 | — | — | 73.3% | -975.9% | -50.2% | -53.5% | — |
 MDGL | $12B | -41.6 | — | — | 94.1% | -31.3% | -42.5% | -29.4% | — |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 SUPN | $3B | -76.9 | 53.4 | 65.5 | 89.6% | -5.1% | -3.7% | -2.8% | 0.7 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 14 years · Updated daily
See ZVRA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ZVRA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ZVRA vs RARE
Side-by-side business, growth, and profitability comparison vs Ultragenyx Pharmaceutical Inc..
Start ComparisonZVRA — Frequently Asked Questions
Quick answers to the most common questions about buying ZVRA stock.
What is Zevra Therapeutics, Inc.'s P/E ratio?
Zevra Therapeutics, Inc.'s current P/E ratio is 8.1x. The historical average is 6.6x. This places it at the 100th percentile of its historical range.
What is Zevra Therapeutics, Inc.'s ROE?
Zevra Therapeutics, Inc.'s return on equity (ROE) is 85.7%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -48.8%.
Is ZVRA stock overvalued?
Based on historical data, Zevra Therapeutics, Inc. is trading at a P/E of 8.1x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Zevra Therapeutics, Inc.'s profit margins?
Zevra Therapeutics, Inc. has 84.5% gross margin and -4.0% operating margin.